FGF9 and myocardial infarction: After myocardial infarction, transgenic FGF9 enhances hypertrophy in the noninfarcted left ventricular myocardium with increased microvessel density, reduces interstitial fibrosis, attenuates fetal gene expression, and improves systolic function and heart failure mortality.